Deutsche Bank reiterated their buy rating on shares of Allergan (NYSE:AGN) in a research report sent to investors on Tuesday morning. The firm currently has a $215.00 price objective on the stock.

Several other research firms have also commented on AGN. Citigroup reduced their price target on shares of Allergan to $215.00 and set a buy rating for the company in a research report on Tuesday. ValuEngine lowered shares of Allergan from a buy rating to a hold rating in a research report on Sunday, December 31st. Royal Bank of Canada set a $218.00 price target on shares of Allergan and gave the company a buy rating in a research report on Thursday, January 4th. Mizuho reaffirmed a buy rating and set a $267.00 price target on shares of Allergan in a research report on Monday, September 25th. Finally, Barclays reaffirmed an equal weight rating on shares of Allergan in a research report on Monday, October 2nd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $226.95.

Allergan (AGN) traded down $1.07 on Tuesday, reaching $176.05. 2,802,192 shares of the company’s stock traded hands, compared to its average volume of 2,980,000. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40. The company has a market cap of $58,910.00, a PE ratio of -7.79, a P/E/G ratio of 1.27 and a beta of 1.11. Allergan has a 1-year low of $160.07 and a 1-year high of $256.80.

Allergan (NYSE:AGN) last posted its earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.06 by $0.09. The business had revenue of $4.03 billion for the quarter, compared to analysts’ expectations of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.32 EPS. research analysts forecast that Allergan will post 16.27 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Friday, November 17th were issued a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.59%. The ex-dividend date was Thursday, November 16th. Allergan’s dividend payout ratio is -12.39%.

Allergan announced that its board has initiated a stock buyback program on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to purchase up to 2.8% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s management believes its stock is undervalued.

In related news, insider William Meury sold 11,807 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $173.89, for a total value of $2,053,119.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Chris W. Bodine purchased 3,030 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was acquired at an average price of $164.77 per share, with a total value of $499,253.10. The disclosure for this purchase can be found here. Insiders purchased a total of 17,630 shares of company stock valued at $2,890,057 over the last three months. 0.36% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the business. Howard Hughes Medical Institute bought a new position in Allergan in the 2nd quarter worth approximately $103,000. Cable Hill Partners LLC boosted its stake in Allergan by 255.2% in the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares during the period. Rockefeller Financial Services Inc. boosted its stake in Allergan by 283.7% in the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares during the period. Massey Quick & Co. LLC boosted its stake in Allergan by 334.8% in the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after purchasing an additional 385 shares during the period. Finally, Pacific Center for Financial Services boosted its stake in Allergan by 1.3% in the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after purchasing an additional 7 shares during the period. Institutional investors and hedge funds own 81.14% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Allergan (AGN) Earns Buy Rating from Deutsche Bank” was reported by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.dailypolitical.com/2018/01/13/allergan-agn-earns-buy-rating-from-deutsche-bank.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.